Ostarine (also known as MK-2866 or Enobosarm) is a selective androgen receptor modulator (SARM) that has been studied for its potential effects on muscle and bone tissue. Scientific interest in Ostarine for the skeletal system arises from its mechanism of action: it binds to androgen receptors, which are present in bone as well as muscle, and can stimulate anabolic activity. Preclinical studies in animal models have demonstrated that Ostarine can increase bone mineral density and improve bone strength, particularly in conditions that mimic osteoporosis or age-related bone loss. Some early-phase clinical trials in humans have also shown that Ostarine may help prevent bone loss and increase lean body mass in populations at risk, such as elderly individuals or those with cancer-induced cachexia.

However, while these findings are promising, no large-scale, long-term clinical trials have conclusively validated Ostarine as a treatment for bone disorders in humans. The compound is not approved by regulatory agencies for use in bone health, and its safety profile, especially with prolonged use, remains uncertain. Therefore, while there is scientific rationale and some supporting evidence for Ostarine’s positive impact on bone health, the evidence is not yet robust or definitive, and more research is needed before it can be recommended for this purpose.